Advertisement

Mastocytosis pp 267-286 | Cite as

International Support and Advocacy for Mast Cell Disease Patients and Caregivers

  • Susan V. JenningsEmail author
  • Valerie M. Slee
  • Jessica S. Hobart
  • Lisa Morrison Thuler
  • David W. Mayne
  • Mercedes Martín-Martínez
  • Shawna L. Lechner-Rumpel
Chapter

Abstract

Support for patients, caregivers, and families affected by mast cell disease, from healthcare providers, patient associations collaborating on an international level, and online forums, can offer key mechanisms through which disease management can be successfully enhanced. Mast cell diseases, including mastocytosis and mast cell activation syndrome (MCAS), are rarely diagnosed maladies involving aberrant cellular growth, activation, and/or function, resulting in heterogeneous symptomatology and presentation. Seen by many specialties, especially allergy/immunology, dermatology, hematology, and gastroenterology, many healthcare providers may not recognize these diseases, necessitating enhanced advocacy by specialists, patients, caregivers, and patient associations. Internationally, patient associations have allied with medical partners, government, and industry entities to help facilitate the patient’s journey, with the goals of diminishing time to diagnosis, improving care, decreasing stress, and enhancing patient/caregiver quality of life.

Keywords

Mast cell disease Mastocytosis Mast cell activation syndrome Hereditary α-tryptasemia Support group Advocacy Patient support Caregiver Physician Rare disease 

Notes

Acknowledgments

The authors thank Jan Hempstead, Rita Barlow, Cheri Smith, Gail Barbera, Rachel Zack, Laureen LaBrash, and Jonathan Lyons for their contributions to and assistance with the preparation of this manuscript.

Disclosures

SVJ: Research Chair, The Mastocytosis Society, Inc.; VMS: Chair, Board of Directors, The Mastocytosis Society, Inc.; JSH: Co-Chair, The UK Mastocytosis Support Group; LMT: President, Associação Brasileira de Mastocitose (Brazilian Mastocytosis Association); DWM: Chair, The Australasian Mastocytosis Society; MMM: Board Member, Asociación Española de Mastocitosis y Enfermedades Relacionadas (Spanish Association for Mastocytosis and Related Diseases); SL-R: Director/President, Mastocytosis Society Canada. The authors have no additional conflicts of interest related to the topics covered in this chapter.

References

  1. 1.
    Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6):1261–70.CrossRefGoogle Scholar
  2. 2.
    Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25.CrossRefGoogle Scholar
  3. 3.
    Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349–55.CrossRefGoogle Scholar
  4. 4.
    Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 2014;34(2):283–95.CrossRefGoogle Scholar
  5. 5.
    Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564–9.Google Scholar
  6. 6.
    Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70–6.CrossRefGoogle Scholar
  7. 7.
    Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin N Am. 2018;38(3):505–25.CrossRefGoogle Scholar
  8. 8.
    Russell N, Jennings S, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: part 2-patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7(4):1157–65.CrossRefGoogle Scholar
  9. 9.
  10. 10.
    Georgin-Lavialle S, Gaillard R, Moura D, Hermine O. Mastocytosis in adulthood and neuropsychiatric disorders. Transl Res. 2016;174:77–85.. e1CrossRefGoogle Scholar
  11. 11.
    Bonadonna P, Pagani M, Aberer W, Bilo MB, Brockow K, Oude Elberink H, et al. Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper. Allergy. 2015;70(7):755–63.CrossRefGoogle Scholar
  12. 12.
    Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120(3):753–9.CrossRefGoogle Scholar
  13. 13.
    Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012;124(23–24):807–14.CrossRefGoogle Scholar
  14. 14.
    El Turki A, Smith H, Llewellyn C, Jones CJ. A systematic review of patients’, parents’ and healthcare professionals’ adrenaline auto-injector administration techniques. Emerg Med J. 2017;34(6):403–16.CrossRefGoogle Scholar
  15. 15.
    Sanchez-Munoz L, Morgado JM, Alvarez-Twose I, Matito A, Garcia-Montero AC, Teodosio C, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol. 2016;172(1):56–63.CrossRefGoogle Scholar
  16. 16.
    Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45.Google Scholar
  17. 17.
    Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389(10069):612–20.CrossRefGoogle Scholar
  18. 18.
    AAP allergy and anaphylaxis emergency plan. 2018. https://www.aap.org/en-us/Documents/AAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf. Accessed 25 July 2018.
  19. 19.
    Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, et al. Mast cell activation syndrome: importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018;142:1008.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Susan V. Jennings
    • 1
    Email author
  • Valerie M. Slee
    • 1
  • Jessica S. Hobart
    • 2
  • Lisa Morrison Thuler
    • 3
  • David W. Mayne
    • 4
  • Mercedes Martín-Martínez
    • 5
  • Shawna L. Lechner-Rumpel
    • 6
  1. 1.The Mastocytosis Society, Inc.SterlingUSA
  2. 2.The UK Mastocytosis Support GroupAltoftsUK
  3. 3.Associação Brasileira de Mastocitose, Volta RedondaRio de JaneiroBrazil
  4. 4.The Australasian Mastocytosis SocietyPort MacquarieAustralia
  5. 5.Asociación Española de Mastocitosis y Enfermedades RelacionadasMadridSpain
  6. 6.Mastocytosis Society CanadaReginaCanada

Personalised recommendations